<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1116">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325259</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN08-VC / FAIR AD</org_study_id>
    <nct_id>NCT01325259</nct_id>
  </id_info>
  <brief_title>FluoroAv45 Imaging Research-in Alzheimer's Disease</brief_title>
  <acronym>FAIR-AD</acronym>
  <official_title>Molecular Imaging of Cerebral Amyloid Plaques Using PET With Fluoro Tracker for Early Diagnosis of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: improving the early detection of AD at prodromal pre-dementia stages has become a&#xD;
      major matter of concern. There is now an important body of literature stating that early&#xD;
      isolated cognitive deficits (Mild Cognitive Impairment-MCI-) predict the risk of developing&#xD;
      AD. Several biomarkers are now available : specific and sensitive neuropsychological&#xD;
      assessments, morphometric evaluation of hippocampal volume and white matter changes by MRI,&#xD;
      cerebrospinal fluid or plasma dosage of Ab fragments and tau proteins, assessment of brain&#xD;
      glucose hypometabolism in temporo-parietal regions with PET [F18]FDG. However, PET imaging&#xD;
      using labelled compounds specifically binding to APs has been suggested to improve the&#xD;
      diagnostic reliability and to potentially help in shortening the delay until formal clinical&#xD;
      diagnosis of AD. F18 AV45 is a new radiotracer which kinetics characteristics allows 10 to 15&#xD;
      minutes acquisition 50 to 60 minutes post injection.&#xD;
&#xD;
      Objectives: The primary objective of the study is to compare F18 AV45 cortical uptake in AD,&#xD;
      MCI patients and Healthy Controls.&#xD;
&#xD;
      Secondary objectives will be to compare cortical uptake of F18 AV45 in MCI subject who will&#xD;
      have convert toward dementia versus those who will not, at two year follow-up period, to&#xD;
      compare level of 18F-AV45 cortical uptake with neuropsychological testing, PET FDG&#xD;
      hypometabolism, ApoE genotype.&#xD;
&#xD;
      Method: Prospective multicentric study. 65 patients expected to enter the study.&#xD;
&#xD;
      Primary outcome measure: Standard Uptake Volume ratios.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard Uptake Value Ratios (SUVr)</measure>
    <time_frame>inclusion</time_frame>
    <description>Standard Uptake Value Ratios (SUVr) in specific regions of interest (ROI) defined by the use of the cerebellum as reference region.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients suffering from Alzheimer's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients suffering from Mild Cognitive Impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 subjects with no cognitive impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neuropsychologic assessment</intervention_name>
    <description>Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[18F]AV-45 PET</intervention_name>
    <description>intravenous injection of 4 MBq/kg of [18F]AV-45</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18-FDG PET</intervention_name>
    <description>intravenous injection of 100 to 120 MBq of FDG</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Magnetic Resonance Imaging</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from Alzheimer's Disease (NINCDS-ADRDA) or from amnesic MCI&#xD;
&#xD;
          -  18 &lt; MMS &lt;= 28 for patients&#xD;
&#xD;
          -  28 &lt;= MMS for healthy volunteers&#xD;
&#xD;
          -  study period &gt; 7 years&#xD;
&#xD;
          -  native language : french&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  affiliated to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  alcoholism in medical history&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  arterial hypertension (180/100 and more)&#xD;
&#xD;
          -  chronical pulmonary disease with hypoxis&#xD;
&#xD;
          -  cranial traumatism with loss of consciousness &gt; 15 minutes&#xD;
&#xD;
          -  severe depressive syndrome or anxiety&#xD;
&#xD;
          -  psychiatric disease in medical history (excepted simple episodes of depression)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Camus</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>university hospital of CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

